Amphastar Pharmaceuticals, Inc.
AMPHAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 18, 2026 | Barclays | $23.00(+8%) | $21.37 | TheFly | |
| Jun 3, 2026 | Barclays | $20.00(+8%) | $18.45 | TheFly | |
| May 14, 2026 | Wells Fargo | Benjamin Burnett | $19.00(+4%) | $18.32 | TheFly |
| May 11, 2026 | Piper Sandler | $21.00(+11%) | $19.00 | TheFly | |
| Apr 20, 2026 | Jefferies | Dennis Ding | $22.00(-4%) | $22.92 | TheFly |
| Dec 8, 2025 | Barclays | $30.00(+15%) | $26.01 | TheFly | |
| Mar 21, 2025 | Piper Sandler | David Amsellem | $32.00(+13%) | $28.29 | TheFly |
| Aug 8, 2024 | Piper Sandler | David Amsellem | $66.00(+52%) | $43.30 | StreetInsider |
| May 23, 2024 | Piper Sandler | David Amsellem | $71.00(+64%) | $43.31 | StreetInsider |
| Mar 12, 2022 | Piper Sandler | David Amsellem | $35.00(+2%) | $34.30 | Pulse 2.0 |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Wells Fargo | maintain | Equal Weight | Nov 6, 2026 |
| Barclays | maintain | Equal Weight | Aug 18, 2026 |
| Wells Fargo | maintain | Equal Weight | Aug 7, 2026 |
| Piper Sandler | maintain | Neutral | Aug 7, 2026 |
| B of A Securities | downgrade | Neutral →Underperform | Jun 29, 2026 |
| Barclays | maintain | Equal Weight | Jun 3, 2026 |
| Wells Fargo | downgrade | Overweight →Equal Weight | May 14, 2026 |
| Piper Sandler | maintain | Neutral | May 11, 2026 |
| Needham | downgrade | Buy →Hold | May 8, 2026 |
| Jefferies | downgrade | Buy →Hold | Apr 21, 2026 |
| Barclays | maintain | Equal Weight | Apr 8, 2026 |
| Wells Fargo | maintain | Overweight | Feb 27, 2026 |
| Needham | maintain | Buy | Feb 27, 2026 |
| Needham | maintain | Buy | Nov 7, 2025 |
| Needham | maintain | Buy | Oct 22, 2025 |
| B of A Securities | maintain | Neutral | Aug 26, 2025 |
| Needham | upgrade | Hold →Buy | Aug 12, 2025 |
| Piper Sandler | maintain | Neutral | Aug 8, 2025 |
| JP Morgan | downgrade | Overweight →Neutral | May 12, 2025 |
| Wells Fargo | maintain | Overweight | May 8, 2025 |
| Needham | maintain | Hold | Apr 10, 2025 |
| Piper Sandler | maintain | Neutral | Mar 21, 2025 |
| Piper Sandler | downgrade | Overweight →Neutral | Feb 4, 2025 |
| Piper Sandler | maintain | Overweight | Aug 8, 2024 |
| Piper Sandler | maintain | Overweight | Jun 27, 2024 |
Earnings History
Next report: Feb 25, 2027 · EPS est. $0.79| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Nov 5, 2026 | $1.14 | $0.86 | $207.6M | $197.5M |
| Aug 6, 2026 | $0.91 | $0.62 | $183.9M | $179.9M |
| May 7, 2026 | $0.42 | $0.70 | $171.2M | $173.5M |
| Feb 26, 2026 | $0.73 | $0.90 | $183.1M | $188.8M |
| Nov 6, 2025 | $0.93 | $0.77 | $191.8M | $190.5M |
| Aug 7, 2025 | $0.85 | $0.71 | $174.4M | $177.1M |
| May 7, 2025 | $0.74 | $0.66 | $170.5M | $173.1M |
| Feb 27, 2025 | $0.92 | $1.01 | $186.5M | $188.8M |
News
Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication William Peters - CFO, Executive VP of Finance, Treasurer & Director Conference Call Participants Ekaterina Knyazkova - JPMorgan Chase & Co, Research Division Naoki Martin - Piper Sandler & Co., Research Division Yuchen Ding - Jefferies LLC, Research Division Serge Belanger - Needham & Company, LLC, Resea…
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amphastar Pharmaceuticals NASDAQ: AMPH reported record third-quarter revenue of $207.6 million, up 8% from a year earlier, as sales of BAQSIMI and Primatene MIST and contributions from newer products offset manufacturing disruptions and lower pricing on some established medicines.
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.93 per share a year ago.
Net revenues of $207.6 million for the three months ended September 30, 2026 GAAP net income of $37.8 million, or $0.87 per share, for the third quarter Adjusted non-GAAP net income of $49.3 million, or $1.14 per share, for the third quarter Company to hold a conference call today at 2:00 p.m. Pacific Time RANCHO CUCAMONGA, Calif.
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
RANCHO CUCAMONGA, Calif., October 29, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that the Company will release results for its third quarter of 2026 ended September 30, 2026, after the market closes on Thursday, November 5, 2026, and will hold a conference call to discuss its financial results at 2:00 p.m.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Valuation and Earnings This table compares Amphastar
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) has been given a consensus recommendation of "Reduce" by the eight analysts that are presently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and six have assigned a hold recommendation to the company. The average twelve-month price target among
Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH - Get Free Report) EVP Rong Zhou sold 10,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, September 16th. The stock was sold at an average price of $23.94, for a total value of $239,400.00. Following the completion of the transaction, the executive vice president owned 169,203
RANCHO CUCAMONGA, Calif., Sept. 1, 2026 /PRNewswire/ -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical Operations, will be presenting at the Wells Fargo 21st Annual Healthcare Conference on Tuesday, September 8th, 2026, at 4:30 pm ET.
The Medical - Generic Drugs industry gains from new launches, biosimilar momentum and portfolio shifts, despite pricing pressure and supply challenges.
AMPH, CHT and HE have been added to the Zacks Rank #5 (Strong Sell) List on August 14, 2026.